Apiam Animal Health Limited (ASX:AHX) would like to advise that the Company has today despatched its Retail Offer Document in respect of the 1 for 4.8 pro-rata non-renounceable entitlement offer announced on 26 May 2022.

Apiam Animal Health Limited (ASX:AHX) refers to its announcement of 19 May 2022 and confirms that it has completed the acquisition of the assets of Romsey Veterinary Service, effective 1 June 2022.

Institutional investors have seen the light by backing regional vet operator Apiam Animal Health Limited (ASX:AHX) to deliver on their ambitious regional expansion strategy.

Apiam Animal Health Limited (ASX:AHX) is pleased to announce it has successfully completed the institutional component of the accelerated entitlement offer (Institutional Entitlement Offer), as announced to the ASX on 26 May 2022.

Apiam Animal Health Limited (ASX:AHX) is pleased to announce the launch of a 1 for 4.8 pro-rata non-renounceable entitlement offer to Eligible Shareholders to raise up $20.25 million before costs.

Apiam Animal Health Limited (ASX:AHX) is pleased to announce it has entered into binding agreements to acquire the assets of Victorian Equine Group and Romsey Veterinary Surgery.

Capitalising on attractive industry tailwinds that have seen the Australian Thoroughbred industry thrive through record prize money which has flowed down to customer spending, Apiam Animal Health Limited (ASX:AHX) is set to open its newest equine hub in Victoria following their acquisition of Victorian Equine Group.

For most pet owners, there is no price too dear for their animal healthcare but with an opportunity to reduce annual expenses most have quickly signed up to the Best Mates program run by Apiam Animal Health Limited (ASX:AHX).

Despite having only received a $700k government grant to build a much needed viral vaccine facility, Apiam Animal Health Limited (ASX:AHX) is already eyeing production within the next 12 months, potentially including one for Japanese Encephalitis which is currently impacting the Australian's pig industry.

As the world emerges from the pandemic which has emphasised the critical importance of vaccination, Apiam Animal Health (ASX:AHX) has identified an opportunity to position Australia as leaders in autogenous vaccine manufacturing.